{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:04:33Z","timestamp":1784786673220,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"DOI":"10.7759\/cureus.113196","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:34:21Z","timestamp":1784784861000},"source":"Crossref","is-referenced-by-count":0,"title":["Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (A\u03b2-mAbs) in Alzheimer\u2019s Disease Patients"],"prefix":"10.7759","author":[{"given":"Wadha","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Al Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Al Marzooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Alsafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Barayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Magalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Quilez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Reche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budour","family":"Alkaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour al dain","family":"Marzouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Rahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Al Mannaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Treatment of Alzheimer disease. (2024). Accessed. 13 July 2026: https:\/\/www.uptodate.com\/contents\/treatment-of-alzheimer-disease."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2013.15.4\/hjahn","article-title":"Memory loss in Alzheimer's disease","volume":"15","author":"Jahn H","year":"2013","unstructured":"Jahn H. Memory loss in Alzheimer's disease. Dialogues Clin Neurosci. 2013, 15:445-54. 10.31887\/DCNS.2013.15.4\/hjahn","journal-title":"Dialogues Clin Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.052936","article-title":"Forget me not: palliative care for people with dementia","volume":"83","author":"Harris D","year":"2007","unstructured":"Harris D. Forget me not: palliative care for people with dementia. Postgrad Med J. 2007, 83:362-6. 10.1136\/pgmj.2006.052936","journal-title":"Postgrad Med J"},{"key":"ref4","unstructured":"Alzheimer\u2019s disease - causes. (2024). Accessed. 13 July 2026: https:\/\/www.nhs.uk\/conditions\/alzheimers-disease\/causes\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer's disease and related dementias","volume":"54","author":"Bellenguez C","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, et al.. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022, 54:412-36. 10.1038\/s41588-022-01024-z","journal-title":"Nat Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2017.01.005","article-title":"Early-onset Alzheimer disease","volume":"35","author":"Mendez MF","year":"2017","unstructured":"Mendez MF. Early-onset Alzheimer disease. Neurol Clin. 2017, 35:263-81. 10.1016\/j.ncl.2017.01.005","journal-title":"Neurol Clin"},{"key":"ref7","unstructured":"What causes Alzheimer's disease?. (2024). Accessed. 13 July 2026: https:\/\/www.nia.nih.gov\/health\/alzheimers-causes-and-risk-factors\/what-causes-alzheimers-disease."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.517","article-title":"Prevalence and economic burden of dementia in the Arab world","volume":"9","author":"Qassem T","year":"2023","unstructured":"Qassem T, Itani L, Nasr W, Al-Ayyat D, Javaid SF, Al-Sinawi H. Prevalence and economic burden of dementia in the Arab world. BJPsych Open. 2023, 9:e126. 10.1192\/bjo.2023.517","journal-title":"BJPsych Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","volume":"14","author":"Kim BH","year":"2025","unstructured":"Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives. Transl Neurodegener. 2025, 14:6. 10.1186\/s40035-025-00465-w","journal-title":"Transl Neurodegener"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2023.2.20220133","article-title":"The future of Alzheimer disease immunotherapies in Saudi Arabia: consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology","volume":"28","author":"Tayeb HO","year":"2023","unstructured":"Tayeb HO, Khallaf RA, Muayqil TA, et al.. The future of Alzheimer disease immunotherapies in Saudi Arabia: consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology. Neurosciences (Riyadh). 2023, 28:77-84. 10.17712\/nsj.2023.2.20220133","journal-title":"Neurosciences (Riyadh)"},{"key":"ref11","unstructured":"Lecanemab. drug information. (2024). Accessed: 13 July 2026: https:\/\/www.uptodate.com\/contents\/lecanemab-drug-information."},{"key":"ref12","unstructured":"Dementia. assessment, management and support. (2018). Accessed: 13 July 2026: https:\/\/www.nice.org.uk\/guidance\/ng97."},{"key":"ref13","unstructured":"Lecanemab for treating mild cognitive impairment or mild dementia. (2024). Accessed. 13 July 2026: https:\/\/www.nice.org.uk\/guidance\/gid-ta11220."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic D","year":"2023","unstructured":"Jeremic D, Navarro-L\u00f3pez JD, Jim\u00e9nez-D\u00edaz L. Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023, 90:102012. 10.1016\/j.arr.2023.102012","journal-title":"Ageing Res Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu CC","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013, 9:106-18. 10.1038\/nrneurol.2012.263","journal-title":"Nat Rev Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder EH","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, et al.. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993, 261:921-3. 10.1126\/science.8346443","journal-title":"Science"},{"key":"ref17","unstructured":"Genetics of Alzheimer disease. (2022). Accessed. 13 July 2026: https:\/\/www.uptodate.com\/contents\/genetics-of-alzheimer-disease."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1567205013666160401115127","article-title":"Alzheimer's disease genetic risk factor APOE-\u03b54 also affects normal brain function","volume":"13","author":"Di Battista AM","year":"2016","unstructured":"Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer's disease genetic risk factor APOE-\u03b54 also affects normal brain function. Curr Alzheimer Res. 2016, 13:1200-7. 10.2174\/1567205013666160401115127","journal-title":"Curr Alzheimer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000118302.66674.e1","article-title":"The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study","volume":"62","author":"Slooter AJ","year":"2004","unstructured":"Slooter AJ, Cruts M, Hofman A, et al.. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology. 2004, 62:1196-8. 10.1212\/01.wnl.0000118302.66674.e1","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.46.3.673","article-title":"Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study","volume":"46","author":"Myers RH","year":"1996","unstructured":"Myers RH, Schaefer EJ, Wilson PW, et al.. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology. 1996, 46:673-7. 10.1212\/wnl.46.3.673","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer LA","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, et al.. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997, 278:1349-56. 10.1001\/jama.1997.03550160069041","journal-title":"JAMA"},{"key":"ref22","unstructured":"DRAGEN secondary analysis platform. (2025). Accessed. 13 July 2026: https:\/\/support.illumina.com\/sequencing\/sequencing_software\/dragen-bio-it-platform.html."},{"key":"ref23","unstructured":"Aligning sequence reads with BWA-MEM. (2013). Accessed. July 2026: https:\/\/arxiv.org\/abs\/1303.3997."},{"key":"ref24","unstructured":"Sentieon genomics tools. (2025). Accessed. 13 July 2026: https:\/\/www.sentieon.com\/."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"Li H","year":"2018","unstructured":"Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018, 34:3094-100. 10.1093\/bioinformatics\/bty191","journal-title":"Bioinformatics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s43588-022-00387","article-title":"Deep learning-based long-read variant calling","volume":"2","author":"Zheng Z","year":"2022","unstructured":"Zheng Z, Li S, Su J, et al.. Deep learning-based long-read variant calling. Nat Comput Sci. 2022, 2:797-803. 10.1038\/s43588-022-00387","journal-title":"Nat Comput Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02024-y","article-title":"Detection of mosaic and population-level structural variants with Sniffles2","volume":"42","author":"Smolka M","year":"2024","unstructured":"Smolka M, Paulin LF, Grochowski CM, et al.. Detection of mosaic and population-level structural variants with Sniffles2. Nat Biotechnol. 2024, 42:1571-80. 10.1038\/s41587-023-02024-y","journal-title":"Nat Biotechnol"},{"key":"ref28","unstructured":"gnomAD. Variant 19-44908684-T-C (v4.1.0). (2024). Accessed. 13 July 2026: https:\/\/gnomad.broadinstitute.org."},{"key":"ref29","unstructured":"gnomAD. Variant 19-44908822-C-T (v4.1.0). (2024). Accessed. 13 July 2026: https:\/\/gnomad.broadinstitute.org."},{"key":"ref30","unstructured":"SNPedia. APOE. (2019). https.\/\/www.snpedia.com\/index.php\/APOE."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek P","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, et al.. Twelve years of SAMtools and BCFtools. Gigascience. 2021, 10:10.1093\/gigascience\/giab008","journal-title":"Gigascience"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2018.07.015","article-title":"A one-penny imputed genome from next-generation reference panels","volume":"103","author":"Browning BL","year":"2018","unstructured":"Browning BL, Zhou Y, Browning SR. A one-penny imputed genome from next-generation reference panels. Am J Hum Genet. 2018, 103:338-48. 10.1016\/j.ajhg.2018.07.015","journal-title":"Am J Hum Genet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.11.1613","article-title":"The effectiveness and value of aducanumab for Alzheimer's disease","volume":"27","author":"Synnott PG","year":"2021","unstructured":"Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD. The effectiveness and value of aducanumab for Alzheimer's disease. J Manag Care Spec Pharm. 2021, 27:1613-7. 10.18553\/jmcp.2021.27.11.1613","journal-title":"J Manag Care Spec Pharm"},{"key":"ref34","unstructured":"Alzheimer\u2019s Association. Aducanumab discontinuation. (2024). Accessed. 13 July 2026: https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/aducanumab."},{"key":"ref35","unstructured":"National Center for Biotechnology Information. dbSNP rs429358. (2025). https.\/\/www.ncbi.nlm.nih.gov\/snp\/rs429358."},{"key":"ref36","unstructured":"National Center for Biotechnology Information. dbSNP rs7412. (2025). https.\/\/www.ncbi.nlm.nih.gov\/snp\/rs7412."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1353\/hub.2005.0058","article-title":"Apolipoprotein E genotyping among the healthy Kuwaiti population","volume":"77","author":"Al-Bustan SA","year":"2005","unstructured":"Al-Bustan SA, Alnaqeeb MA, Annice BG, Ibrhim G, Al-Rubaian J, Ahmed AH, Refai TM. Apolipoprotein E genotyping among the healthy Kuwaiti population. Hum Biol. 2005, 77:487-98. 10.1353\/hub.2005.0058","journal-title":"Hum Biol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2004.361","article-title":"Apolipoprotein E polymorphism and lipoprotein levels in a Gulf Arab population in Kuwait: a pilot study","volume":"24","author":"Al-Shammari S","year":"2004","unstructured":"Al-Shammari S, Fatania H, Al-Radwan R, Akanji AO. Apolipoprotein E polymorphism and lipoprotein levels in a Gulf Arab population in Kuwait: a pilot study. Ann Saudi Med. 2004, 24:361-4. 10.5144\/0256-4947.2004.361","journal-title":"Ann Saudi Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2018.1.20170169","article-title":"APOE gene polymorphism among Jordanian Alzheimer`s patients with relation to lipid profile","volume":"23","author":"Shafagoj YA","year":"2018","unstructured":"Shafagoj YA, Naffa RG, El-Khateeb MS, et al.. APOE gene polymorphism among Jordanian Alzheimer`s patients with relation to lipid profile. Neurosciences (Riyadh). 2018, 23:29-34. 10.17712\/nsj.2018.1.20170169","journal-title":"Neurosciences (Riyadh)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.630502","article-title":"APOE and Alzheimer's disease: from lipid transport to physiopathology and therapeutics","volume":"15","author":"Husain MA","year":"2021","unstructured":"Husain MA, Laurent B, Plourde M. APOE and Alzheimer's disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021, 15:630502. 10.3389\/fnins.2021.630502","journal-title":"Front Neurosci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089595","article-title":"Search for the fourth elusive haplotype of the APO E2\/E3\/E4 polymorphism and its potential effect on AD risk","volume":"20","author":"Cheema AN","year":"2024","unstructured":"Cheema AN, Lawrence EC, Zafari N, et al.. Search for the fourth elusive haplotype of the APO E2\/E3\/E4 polymorphism and its potential effect on AD risk. Alzheimers Dement. 2024, 20:10.1002\/alz.089595","journal-title":"Alzheimers Dement"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-016-0804-x","article-title":"The neurobiology and age-related prevalence of the \u03b54 allele of apolipoprotein E in Alzheimer's disease cohorts","volume":"60","author":"Heffernan AL","year":"2016","unstructured":"Heffernan AL, Chidgey C, Peng P, Masters CL, Roberts BR. The neurobiology and age-related prevalence of the \u03b54 allele of apolipoprotein E in Alzheimer's disease cohorts. J Mol Neurosci. 2016, 60:316-24. 10.1007\/s12031-016-0804-x","journal-title":"J Mol Neurosci"},{"key":"ref43","unstructured":"Drugs@FDA. FDA-Approved Drugs - Aduhelm. (2021). Accessed: July 2026: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761178."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings J","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al.. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023, 10:362-77. 10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490056-landscape-of-apolipoprotein-apoe-in-the-emirati-population-and-recommendations-for-a-genotyping-approach-for-amyloid-beta-monoclonal-antibodies-a-mabs-in-alzheimers-disease-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:34:26Z","timestamp":1784784866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490056-landscape-of-apolipoprotein-apoe-in-the-emirati-population-and-recommendations-for-a-genotyping-approach-for-amyloid-beta-monoclonal-antibodies-a-mabs-in-alzheimers-disease-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.113196","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}